HLS Therapeutics (TSX:HLS) Moat Score: 4/10 (As of Jun. 29, 2026)


TSX:HLS HLS Therapeutics Inc TSX:HLS
62 GF Score
Price C$4.14
GF Value C$4.47
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics Moat Score?

HLS Therapeutics TSX:HLS -2.82% 62 Moat Score is 4 as of Jun. 29, 2026. GuruFocus rates TSX:HLS with a GF Score™ of 62/100 and a GF Value™ of C$4.47 (Fairly Valued). The stock has 4 warning signs investors should review. Among 1,030 Drug Manufacturers companies, HLS Therapeutics ranks better than 90.68% on this metric.

HLS Therapeutics has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

HLS Therapeutics has Narrow Moat: HLS Therapeutics has a discernible but modest moat due to its valuable intellectual property and patents in the pharmaceutical sector. However, it faces intense competition and lacks the scale and brand strength for a stronger moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes HLS Therapeutics might have Narrow Moat - Discernible but modest moat.

HLS Therapeutics  (TSX:HLS) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

HLS Therapeutics Moat Score Related Terms

TSX:HLS vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

HLS Therapeutics Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's Moat Score falls into.


TSX:HLS
62GF Score
HLS Therapeutics Inc TSX:HLS
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
HLS Therapeutics (TSX:HLS) has a Moat Score of 4 as of Jun. 29, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, HLS Therapeutics ranks #96 out of 1030 companies in the Drug Manufacturers industry, placing it in the top 9.3%.
Is HLS Therapeutics' Moat Score too high?
HLS Therapeutics' current Moat Score is 4. Based on the distribution chart, HLS Therapeutics ranks #96 out of 1030 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, HLS Therapeutics ranks #96 out of 1030 companies for Moat Score. This places HLS Therapeutics in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. HLS Therapeutics's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.47, compared to a current price of C$4.14 — trading 7.4% below its estimated fair value. The current Moat Score is 4. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Moat Score is 4 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.14 is trading 7.4% below its estimated GF Value™ of C$4.47. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

  • Moat Score: 4
  • GF Value™: C$4.47 vs. price of C$4.14 (7.4% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score

Get the complete analysis for TSX:HLS

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.14
Price
C$4.47
GF Value